Watch
GLUE
Monte Rosa Therapeutics, Inc.
Healthcare · Biotechnology · small-cap ($1.3B)
-27.5%
from rolling 252-day high of $25.77 set 2026-01-08 · 126d ago
Current
$18.68
Decline depth
-27.5%
Decline σ
4.1σ
TFC
3/5 bearish
Rolling 252-day high Up day Down day Last 90 trading days · data from Alpaca

Structural break signals

GLUE qualifies for the Watch on decline depth.

Decline depth
-27.5%
From rolling 252-day high of $25.77, 126d ago. Past the 20% Watch threshold.
Time-frame continuity
3/5 bearish
Latest bar across daily/weekly/monthly/quarterly/yearly time frames. A bar counts as bearish when it's a 2-Down or a red 3. Past the 3/5 Watch threshold.
Decline sigma
4.1σ
Drop from local high over the last 20 bars, expressed in units of the stock's typical daily volatility (3.37% per day). Past the ≥4σ Watch threshold.

The structural read

What price action says about GLUE.

GLUE qualifies for the Watch on decline depth — down -27.5% from its rolling 252-day high.

Cross-confirmation: also showing 3/5 bearish time frames.

Cross-confirmation: decline sigma also reads 4.1σ over 20 bars.

Upstream TFC read: bearish alignment, current phase daily. Last bar types — daily 3 (red), weekly 2U (red), monthly 1 (red).

Earnings on file: 2026-03-17. Tiering is unaffected by earnings dates — listings reflect price structure only.

52-week range

52W low $3.50 68.2% of range 52W high $25.77

Sector context · Healthcare

182 other Healthcare tickers are on Broken Stocks.

93 Red List
43 Amber
46 Watch
-35.8% Median decline

Worst in sector: OPRX (-76.7%). Least-bad: ANIP (-20.0%). See all Healthcare listings →

Questions about GLUE

What people ask.

Why is GLUE on Broken Stocks?

GLUE qualifies for the Watch on decline depth. It is down -27.5% from its rolling 252-day high of $25.77, set on 2026-01-08 — 126d ago.

Is GLUE a falling knife?

No. The falling-knife label usually implies a steep, severe drop — typically 30% or more from a fresh high. GLUE is down -27.5% from its 52-week high, which qualifies for the Watch tier but is shallower than the falling-knife pattern. It's an early-stage decline rather than a sharp breakdown.

Is GLUE a buy?

Broken Stocks does not issue buy or sell recommendations. The list is a rules-based technical warning system. It tracks structural decline depth and recency — not company quality, management, fundamentals, or news. Always do your own research and consult a licensed advisor.

Where is GLUE trading inside its 52-week range?

At $18.68, GLUE sits 68.2% of the way from its 52-week low ($3.50) to its 52-week high ($25.77). A reading below 25% indicates price is hugging the bottom of the range; above 75%, the top.

How fast has GLUE been declining?

The current 27.5% decline accrued over 126d, which annualizes to roughly -79.7% per year. Annualized pace is a sanity check — a 30% decline in three months is a different signal than a 30% decline over two years.

How does GLUE compare to its sector?

There are 182 other Healthcare tickers on Broken Stocks: 93 Red, 43 Amber, 46 Watch, with 55 showing recovering structural signals. Median sector decline is -35.8% — GLUE's decline is shallower than the sector median.

Does GLUE's earnings date affect its tier?

No. Tiering is decided purely by decline depth and recency of the rolling-high date. The earnings date on file (2026-03-17) is shown for reference only — listings can move tier between scans based on closing prices, regardless of fundamentals or news events.